These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 25249180)

  • 21. Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.
    Humphreys PG; Atkinson SJ; Bamborough P; Bit RA; Chung CW; Craggs PD; Cutler L; Davis R; Ferrie A; Gong G; Gordon LJ; Gray M; Harrison LA; Hayhow TG; Haynes A; Henley N; Hirst DJ; Holyer ID; Lindon MJ; Lovatt C; Lugo D; McCleary S; Molnar J; Osmani Q; Patten C; Preston A; Rioja I; Seal JT; Smithers N; Sun F; Tang D; Taylor S; Theodoulou NH; Thomas C; Watson RJ; Wellaway CR; Zhu L; Tomkinson NCO; Prinjha RK
    J Med Chem; 2022 Feb; 65(3):2262-2287. PubMed ID: 34995458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-Based Design of a Bromodomain and Extraterminal Domain (BET) Inhibitor Selective for the N-Terminal Bromodomains That Retains an Anti-inflammatory and Antiproliferative Phenotype.
    Wellaway CR; Bamborough P; Bernard SG; Chung CW; Craggs PD; Cutler L; Demont EH; Evans JP; Gordon L; Karamshi B; Lewis AJ; Lindon MJ; Mitchell DJ; Rioja I; Soden PE; Taylor S; Watson RJ; Willis R; Woolven JM; Wyspiańska BS; Kerr WJ; Prinjha RK
    J Med Chem; 2020 Sep; 63(17):9020-9044. PubMed ID: 32787145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
    Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
    Shi J; Vakoc CR
    Mol Cell; 2014 Jun; 54(5):728-36. PubMed ID: 24905006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and Characterization of Novel Covalent Bromodomain and Extra-Terminal Domain (BET) Inhibitors Targeting a Methionine.
    Kharenko OA; Patel RG; Brown SD; Calosing C; White A; Lakshminarasimhan D; Suto RK; Duffy BC; Kitchen DB; McLure KG; Hansen HC; van der Horst EH; Young PR
    J Med Chem; 2018 Sep; 61(18):8202-8211. PubMed ID: 30165024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC).
    Zhang M; Zhang Y; Song M; Xue X; Wang J; Wang C; Zhang C; Li C; Xiang Q; Zou L; Wu X; Wu C; Dong B; Xue W; Zhou Y; Chen H; Wu D; Ding K; Xu Y
    J Med Chem; 2018 Apr; 61(7):3037-3058. PubMed ID: 29566488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery, X-ray Crystallography, and Anti-inflammatory Activity of Bromodomain-containing Protein 4 (BRD4) BD1 Inhibitors Targeting a Distinct New Binding Site.
    Liu Z; Li Y; Chen H; Lai HT; Wang P; Wu SY; Wold EA; Leonard PG; Joseph S; Hu H; Chiang CM; Brasier AR; Tian B; Zhou J
    J Med Chem; 2022 Feb; 65(3):2388-2408. PubMed ID: 34982556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent and selective bivalent inhibitors of BET bromodomains.
    Waring MJ; Chen H; Rabow AA; Walker G; Bobby R; Boiko S; Bradbury RH; Callis R; Clark E; Dale I; Daniels DL; Dulak A; Flavell L; Holdgate G; Jowitt TA; Kikhney A; McAlister M; Méndez J; Ogg D; Patel J; Petteruti P; Robb GR; Robers MB; Saif S; Stratton N; Svergun DI; Wang W; Whittaker D; Wilson DM; Yao Y
    Nat Chem Biol; 2016 Dec; 12(12):1097-1104. PubMed ID: 27775716
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
    Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
    Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition.
    Theodoulou NH; Bamborough P; Bannister AJ; Becher I; Bit RA; Che KH; Chung CW; Dittmann A; Drewes G; Drewry DH; Gordon L; Grandi P; Leveridge M; Lindon M; Michon AM; Molnar J; Robson SC; Tomkinson NC; Kouzarides T; Prinjha RK; Humphreys PG
    J Med Chem; 2016 Feb; 59(4):1425-39. PubMed ID: 25856009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
    McLure KG; Gesner EM; Tsujikawa L; Kharenko OA; Attwell S; Campeau E; Wasiak S; Stein A; White A; Fontano E; Suto RK; Wong NC; Wagner GS; Hansen HC; Young PR
    PLoS One; 2013; 8(12):e83190. PubMed ID: 24391744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.
    Jiménez I; Baruchel A; Doz F; Schulte J
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27900832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [1,2,4]triazolo[4,3-a]phthalazines: inhibitors of diverse bromodomains.
    Fedorov O; Lingard H; Wells C; Monteiro OP; Picaud S; Keates T; Yapp C; Philpott M; Martin SJ; Felletar I; Marsden BD; Filippakopoulos P; Müller S; Knapp S; Brennan PE
    J Med Chem; 2014 Jan; 57(2):462-76. PubMed ID: 24313754
    [TBL] [Abstract][Full Text] [Related]  

  • 36. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
    Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
    Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery and lead identification of quinazoline-based BRD4 inhibitors.
    Yang SM; Urban DJ; Yoshioka M; Strovel JW; Fletcher S; Wang AQ; Xu X; Shah P; Hu X; Hall MD; Jadhav A; Maloney DJ
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3483-3488. PubMed ID: 30268702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.
    Sperandio D; Aktoudianakis V; Babaoglu K; Chen X; Elbel K; Chin G; Corkey B; Du J; Jiang B; Kobayashi T; Mackman R; Martinez R; Yang H; Zablocki J; Kusam S; Jordan K; Webb H; Bates JG; Lad L; Mish M; Niedziela-Majka A; Metobo S; Sapre A; Hung M; Jin D; Fung W; Kan E; Eisenberg G; Larson N; Newby ZER; Lansdon E; Tay C; Neve RM; Shevick SL; Breckenridge DG
    Bioorg Med Chem; 2019 Feb; 27(3):457-469. PubMed ID: 30606676
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bromodomains: a new target class for drug development.
    Cochran AG; Conery AR; Sims RJ
    Nat Rev Drug Discov; 2019 Aug; 18(8):609-628. PubMed ID: 31273347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The making of I-BET762, a BET bromodomain inhibitor now in clinical development.
    Zhao Y; Yang CY; Wang S
    J Med Chem; 2013 Oct; 56(19):7498-500. PubMed ID: 24107192
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.